目的：通过使用频域相干光学断层深度增强成像测量正常个体脉络膜厚度(CT)以评估眼部使用0.15%酒石酸溴莫尼定对眼后节的潜在影响。

方法：前瞻性、安慰剂对照干预性临床试验，包括32例32眼正常个体。第1d，受试者接受一滴无防腐剂人工泪液作为安慰剂； 第2d，接受一滴0.15%酒石酸溴莫尼定。收集每次用药前及用药后1、3和5h，眼压，眼灌注压(OPP)以及EDI-SD-OCT数据。

结果：相较于最初测量结果，局部应用0.15%酒石酸溴莫尼定后，在下凹(P=0.001)，颞凹1500μm 处(P=0.003)，鼻凹1500μm处(P=0.003)测得脉络膜厚度显著增加。整个研究过程中，安慰剂组脉络膜厚度未发生变化(P>0.05)。分别使用安慰剂和溴莫尼定后眼灌注压没有显著降低(P>0.05)。研究中未观察到不良反应。

结论：与预期相悖，局部应用0.15%酒石酸溴莫尼定导致下凹、颞凹、鼻凹处脉络膜厚度增加。这一结论可能与脉络膜血管自动调节机制有关。

METHODS: Thirty-two eyes of 32 healthy subjects were included in this prospective, placebo-controlled interventional clinical trial. They received one drop of topical preservative-free artificial tears as placebo for the first day and one drop of brimonidine-purite 0.15% for the second day. Intraocular pressure, ocular perfusion pressure(OPP), and EDI-SD-OCT were performed at baseline, at 1, 3 and 5h after the treatments.

RESULTS: Compared to the measurements obtained at baseline, the CT measurements obtained after the topical application of brimonidine-purite 0.15% significantly increased at the sub-fovea(P=0.001), at temporal 1500 μm to the fovea(P=0.003)and at nasal 1500 μm to the fovea(P=0.003). Choroidal thickness was unchanged in placebo group during the study(P >0.05). There was no significant reduction in the OPP in both groups(P >0.05). There were no adverse events during the study.

CONCLUSIONS: Contrary to expectations, topical administration of brimonidine-purite 0.15% resulted with thickening of sub-foveal, temporal and nasal CT. This might be related to altered auto-regulation mechanisms in choroidal vessels.